Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.39 |
| ▸ | DRD1 | P21728 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL231127 | 0.81 | CYP2D6 (0.57) | CYP2D6CYP2C19L3MBTL1CHRM2ADRA2A | |
| SCHEMBL4033315 | 0.80 | CYP2D6 (0.39) | CYP2D6CYP2C19L3MBTL1CHRM2ADRA2A | |
| SCHEMBL10886684 | 0.79 | CYP2D6 (0.44) | CYP2D6CYP2C19L3MBTL1CHRM2ADRA2A | |
| SCHEMBL5178057 | 0.79 | CYP2D6 (0.44) | CYP2D6CYP2C19L3MBTL1CHRM2ADRA2A | |
| Methane SCHEMBL28533749 | 0.79 | CYP2D6 (0.55) | CYP2D6CYP2C19L3MBTL1CHRM2ADRA2A | |
| Hydrochloric Acid SCHEMBL6775520 | 0.79 | CYP2D6 (0.55) | CYP2D6CYP2C19L3MBTL1CHRM2ADRA2A | |
| SCHEMBL13367399 | 0.77 | SIGMAR1 (0.47) | CYP2D6CYP2C19L3MBTL1CHRM2ADRA2A | |
| SCHEMBL18712613 | 0.77 | CYP2D6 (0.46) | CYP2D6CYP2C19L3MBTL1CHRM2ADRA2A | |
| SCHEMBL2620728 | 0.76 | ACHE (0.50) | SLC6A2SLC6A4LMNAALDH1A1CYP1A2 | |
| SCHEMBL6752665 | 0.74 | CYP2D6 (0.40) | CYP2D6CYP2C19L3MBTL1CHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230292586-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-09-14 | — | — | US | disclosed |
| EP-3430013-A1 | CARBAPENEM COMPOUNDS | Orchid Pharma Limited (IN) | 2019-01-23 | — | — | EP | disclosed |
| WO-2017158616-A1 | CARBAPENEM COMPOUNDS | ORCHID PHARMA LTD. (IN) | 2017-09-21 | — | — | WO | disclosed |
| EP-1999119-A2 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | Abbott Laboratories (US) | 2008-12-10 | — | — | EP | disclosed |
| US-7378412-B2 | Pharmaceutical compounds | NICOX S.A. (FR) | 2008-05-27 | — | — | US | disclosed |
| EP-1861100-A1 | 3 , llB-CIS-DIHYDROTETRABENAZINE FOR THE TREATMENT OF A PROLIFERATIVE DISEASE OR AN INFLAMMATION | Cambridge Laboratories (Ireland) Limited (IE) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007095602-A2 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBOTT LABORATORIES (US) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007017643-A1 | 3 , llB-CIS-DIHYDROTETRABENAZINE FOR THE TREATMENT OF A PROLIFERATIVE DISEASE OR AN INFLAMMATION | CAMBRIDGE LABORATORIES (IRELAND) LIMITED (IE) | 2007-02-15 | — | — | WO | disclosed |
| US-20050261242-A1 | Pharmaceutical compounds | NICOX, S.A. | 2005-11-24 | — | — | US | disclosed |
| US-6344561-B2 | TREATMENT OF SKIN DISORDERS, INFLAMMATION, NERVE SYSTEM DISORDERS, CANCER | ALLERGAN SALES, INC. | 2002-02-05 | — | — | US | disclosed |
| WO-1991017172-A1 | NOVEL MYCALAMIDES WITH ANTITUMOR AND ANTIVIRAL ACTIVITY | HARBOR BRANCH OCEANOGRAPHIC INSTITUTION, INC. (US) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261242-A1 | Pharmaceutical compounds | CYP2B6, CYP2C19, MAOB | CYP2D6 11/4885CYP2C19 2/4885L3MBTL1 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.